Presentation is loading. Please wait.

Presentation is loading. Please wait.

ATX-101 for reduction of submental fat: A phase III randomized controlled trial  Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,

Published byΔράκων Ακρίδας Modified over 5 years ago

Similar presentations

Presentation on theme: "ATX-101 for reduction of submental fat: A phase III randomized controlled trial  Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,"— Presentation transcript:

1 ATX-101 for reduction of submental fat: A phase III randomized controlled trial 
Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA, Vince Bertucci, MD, Patricia Walker, MD, PhD, Daniel R. Lee, MS, Paul F. Lizzul, MD, PhD, MPH, MBA, Todd M. Gross, PhD, Frederick C. Beddingfield, MD, PhD  Journal of the American Academy of Dermatology  Volume 75, Issue 4, Pages e7 (October 2016) DOI: /j.jaad Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 A, Standardized photographs and magnetic resonance imaging (MRI) of a 51-year-old man who underwent 6 treatment sessions with ATX-101 and achieved a composite improvement of 1 or more grades (Clinician-Reported Submental Fat Rating Scale [CR-SMFRS]/Patient-Reported Submental Fat Rating Scale [PR-SMFRS]) at 12 weeks after last treatment. Percentage reduction in submental volume as assessed by MRI was 14%. B, Standardized photographs and MRI of a 56-year-old woman who underwent 5 treatment sessions with ATX-101 and achieved a composite improvement of 1 or more grades (CR-SMFRS/PR-SMFRS) at 12 weeks after last treatment. Percentage reduction in submental volume as assessed by MRI was 2%. C, Standardized photographs of a 43-year-old woman who underwent 4 treatment sessions with ATX-101 and achieved a composite improvement of 2 or more grades (CR-SMFRS/PR-SMFRS) at 12 weeks after last treatment. BMI, Body mass index; PR-SMFIS, Patient-Reported Submental Fat Impact Scale; SMSLG, Submental Skin Laxity Grade; SSRS, Subject Self-Rating Scale. Journal of the American Academy of Dermatology  , e7DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 1 A, Standardized photographs and magnetic resonance imaging (MRI) of a 51-year-old man who underwent 6 treatment sessions with ATX-101 and achieved a composite improvement of 1 or more grades (Clinician-Reported Submental Fat Rating Scale [CR-SMFRS]/Patient-Reported Submental Fat Rating Scale [PR-SMFRS]) at 12 weeks after last treatment. Percentage reduction in submental volume as assessed by MRI was 14%. B, Standardized photographs and MRI of a 56-year-old woman who underwent 5 treatment sessions with ATX-101 and achieved a composite improvement of 1 or more grades (CR-SMFRS/PR-SMFRS) at 12 weeks after last treatment. Percentage reduction in submental volume as assessed by MRI was 2%. C, Standardized photographs of a 43-year-old woman who underwent 4 treatment sessions with ATX-101 and achieved a composite improvement of 2 or more grades (CR-SMFRS/PR-SMFRS) at 12 weeks after last treatment. BMI, Body mass index; PR-SMFIS, Patient-Reported Submental Fat Impact Scale; SMSLG, Submental Skin Laxity Grade; SSRS, Subject Self-Rating Scale. Journal of the American Academy of Dermatology  , e7DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

4 Fig 1 A, Standardized photographs and magnetic resonance imaging (MRI) of a 51-year-old man who underwent 6 treatment sessions with ATX-101 and achieved a composite improvement of 1 or more grades (Clinician-Reported Submental Fat Rating Scale [CR-SMFRS]/Patient-Reported Submental Fat Rating Scale [PR-SMFRS]) at 12 weeks after last treatment. Percentage reduction in submental volume as assessed by MRI was 14%. B, Standardized photographs and MRI of a 56-year-old woman who underwent 5 treatment sessions with ATX-101 and achieved a composite improvement of 1 or more grades (CR-SMFRS/PR-SMFRS) at 12 weeks after last treatment. Percentage reduction in submental volume as assessed by MRI was 2%. C, Standardized photographs of a 43-year-old woman who underwent 4 treatment sessions with ATX-101 and achieved a composite improvement of 2 or more grades (CR-SMFRS/PR-SMFRS) at 12 weeks after last treatment. BMI, Body mass index; PR-SMFIS, Patient-Reported Submental Fat Impact Scale; SMSLG, Submental Skin Laxity Grade; SSRS, Subject Self-Rating Scale. Journal of the American Academy of Dermatology  , e7DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

5 Fig 2 Mean change from baseline in the Total Scale Score and individual component scores of the Patient-Reported Submental Fat Impact Scale (PR-SMFIS) at 12 weeks after last treatment. P < .001 for all comparisons between ATX-101 and placebo. Tx, Treatment. Journal of the American Academy of Dermatology  , e7DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

6 Fig 3 Incidence, severity, and duration of injection-site adverse events (AE) (swelling/edema, bruising, and pain) for individual treatment sessions. At the top of the graph, the number of patients reporting the AE is listed in the first row; the total number of patients is listed in the second row. The number listed at the top of each bar is the median duration of the AE in a particular session. For session frequency, the data for the percentage of sessions for which the AE was reported are shown. A, ATX-101; P, placebo. Journal of the American Academy of Dermatology  , e7DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

7 Supplementary Fig 1 Study design. aPosttreatment, relative to the patient's last treatment session, irrespective of when that occurred. Analyses were made after the last patient completed visit 9 (week 32; 12 weeks after last treatment). MRI, Magnetic resonance imaging. Journal of the American Academy of Dermatology  , e7DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

8 Supplementary Fig 2 Patient disposition. The intent-to-treat population included all randomized patients and was used to evaluate efficacy. Magnetic resonance imaging (MRI) assessments were conducted on a subgroup of the intent-to-treat population. The safety population included all randomized patients who received 1 or more injections of study drug and was used to evaluate safety. SMF, Submental fat. Journal of the American Academy of Dermatology  , e7DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

9 Supplementary Fig 3 Photonumeric guide for assessment of submental fat (SMF) using the Clinician-Reported Submental Fat Rating Scale. Adapted from McDiarmid J, Ruiz JB, Lee D, et al. Results from a pooled analysis of two European, randomized, placebo-controlled, phase 3 studies of ATX-101 for the pharmacologic reduction of excess submental fat. Aesthetic Plast Surg. 2014;38: Journal of the American Academy of Dermatology  , e7DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

10 Supplementary Fig 4 Photonumeric guide for assessment of skin laxity using the Submental Skin Laxity Grade scale. Reproduced with permission from Jones DH, Carruthers J, Joseph JH, et al. REFINE-1, a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial with ATX-101, an injectable drug for submental fat reduction. Dermatol Surg. 2016;42: Journal of the American Academy of Dermatology  , e7DOI: ( /j.jaad ) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "ATX-101 for reduction of submental fat: A phase III randomized controlled trial  Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,"

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.
A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold.

A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold.
A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in.

A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.
Macrene R. Alexiades-Armenakas, MD, Jeffrey S. Dover, MD, Kenneth A

Macrene R. Alexiades-Armenakas, MD, Jeffrey S. Dover, MD, Kenneth A
Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 
Diacerein orphan drug development for epidermolysis bullosa simplex: A phase 2/3 randomized, placebo-controlled, double-blind clinical trial  Verena Wally,

Diacerein orphan drug development for epidermolysis bullosa simplex: A phase 2/3 randomized, placebo-controlled, double-blind clinical trial  Verena Wally,
A randomized controlled crossover trial: Lidocaine injected at a 90-degree angle causes less pain than lidocaine injected at a 45-degree angle  Kathryn.

A randomized controlled crossover trial: Lidocaine injected at a 90-degree angle causes less pain than lidocaine injected at a 45-degree angle  Kathryn.
Thomas B. Casale, MD, Patrick H. Win, MD, Jonathan A

Thomas B. Casale, MD, Patrick H. Win, MD, Jonathan A
Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis  Lawrence F. Eichenfield, MD, Robert S. Call,

Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis  Lawrence F. Eichenfield, MD, Robert S. Call,
Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery 

Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery 
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional.

Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional.
Alopecia after injection of ATX-101 for reduction of submental fat

Alopecia after injection of ATX-101 for reduction of submental fat
ATX-101 for reduction of submental fat: A phase III randomized controlled trial  Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,

ATX-101 for reduction of submental fat: A phase III randomized controlled trial  Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data  Bruce Strober, MD,

Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data  Bruce Strober, MD,
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.
Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.
Macrene R. Alexiades-Armenakas, MD, Jeffrey S. Dover, MD, Kenneth A

Macrene R. Alexiades-Armenakas, MD, Jeffrey S. Dover, MD, Kenneth A

Similar presentations

Ads by Google